TABLE 1.
Clinical characteristics of cancer patients receiving systemic therapy with prior severe acute respiratory syndrome coronavirus 2 infection
| Patient | Sex | Age years | PS | Cancer diagnosis | Staging | Chronic diseases | Systemic therapy | Time of systemic therapy | Grade of neutropenia | Time of nucleic acid testing |
| 1 | Female | 56 | 1 | NSCLC | T3N2M1 | Diabetes | 2 cycles of paclitaxel+nedaplatin | 21 Apr, 14 May | 2 | 20 Apr, 13 May, 9 Jun |
| 2 | Male | 70 | 1 | NSCLC | T4N2M0 | COPD | 4 cycles of vinorelbine+anlotinib | 3 Apr, 30 Apr, 22 May, 16 Jun | 0 | 21 Feb, 2 Apr, 28 Apr, 15 May, 15 Jun |
| 3 | Female | 33 | 1 | NSCLC | T4N3M1 | None | 2 cycles of PP, 3 cycles of PP+bevacizumab | 20 Mar, 13 May, 4 Jun, 25 Jun, 16 Jul | 0 | 18 Mar, 2 Apr, 12 May, 1 Jun, 22 Jun, 14 Jul |
| 4 | Female | 67 | 1 | NSCLC | T4N0M0 | Hypertension and diabetes | 2 cycles of GP | 7 Apr, 13 May | 2 | 6 Apr, 20 Apr, 11 May, 10 Jul |
| 5 | Male | 59 | 1 | NSCLC | T3N1M0 | None | 4 cycles of DP | 4 Apr, 11 May, 3 Jun, 26 Jun | 1 | 3 Apr, 8 May, 27 May, 24 Jun |
| 6 | Male | 73 | 1 | NSCLC | T3N2M0 | None | 4 cycles of abraxane+nedaplatin | 11 Apr, 5 May, 3 Jun, 25 Jun | 2 | 9 Apr, 4 May, 1 Jun, 23 Jun |
| 7 | Female | 59 | 1 | NSCLC | T3N3M1 | None | 2 cycles of docetaxel+nedaplatin and 1 cycle of GP | 13 Mar, 18 Apr, 18 Jun | 2 | 10 Mar, 15 Apr, 26 May, 10 Jun, 15 Jun, 8 Jul, 13 Jul |
| 8 | Male | 72 | 1 | NSCLC | T3N1M0 | Hypertension, cardiovascular disease and COPD | 2 cycles of abraxane and 2 cycles of abraxane+nedaplatin+PD-1 inhibitor | 25 Mar, 6 May, 6 Jun, 1 Jul | 3 | 23 Mar, 1 Apr, 3 Apr, 5 May, 3 Jun, 29 Jun |
| 9 | Male | 64 | 1 | Lung neuroendocrine carcinoma | T4N3M0 | Hypertension | 3 cycles of abraxane+lobaplatin | 21 Apr, 19 May, 18 Jun | 4 | 19 Apr, 18 May, 15 Jun |
| 10 | Female | 64 | 1 | Breast cancer | T3N1M0 | Diabetes | 3 cycles of capecitabine and 2 cycles of docetaxel | 10 Apr, 1 May, 23 May, 12 Jun, 4 Jul, 24 Jul | 1 | 9 Apr, 14 Apr, 23 Apr, 16 May, 8 Jun, 2 Jul, 21 Jul |
| 11 | Female | 49 | 2 | Breast cancer | T2N0M1 | None | 5 cycles of capecitabine+letrozole | 18 Mar, 15 Apr, 30 May, 22 Jun, 23 Jul | 0 | 17 Mar, 20 Mar, 14 Apr, 28 May, 22 Jul |
| 12 | Female | 45 | 1 | Breast cancer | T2N2M1 | None | 6 cycles of capecitabine+trastuzumab+partuzumab | 15 Apr, 5 May, 28 May, 17 Jun, 7 Jul, 28 Jul | 0 | 14 Apr, 29 Apr, 11 May, 26 May, 12 Jun, 6 Jul, 27 Jul |
| 13 | Female | 37 | 1 | Breast cancer | T3N2M0 | None | 3 cycles of capecitabine and 2 cycles of AC | 26 Mar, 16 Apr, 25 May, 17 Jun, 18 Jul | 2 | 25 Mar, 15 Apr, 22 May, 15 Jun, 16 Jul |
| 14 | Female | 30 | 1 | Breast cancer | T2N0M0 | None | 4 cycles of AC and 1 cycle of docetaxel | 28 Mar, 22 May, 9 Jun, 30 Jun, 22 Jul | 3 | 27 Mar, 7 Apr, 21 May, 6 Jun, 26 Jun, 20 Jul |
| 15 | Female | 63 | 1 | Breast cancer | T1N1M0 | Hypertension | 4 cycles of docetaxel | 15 Mar, 19 Apr, 13 May, 19 Jun | 1 | 13 Mar, 18 Apr, 10 May, 23 May, 17 Jun |
| 16 | Female | 53 | 1 | Breast cancer | T4N3M1 | Hypertension | 5 cycles of capecitabine | 18 Mar, 14 Apr, 13 May, 4 Jun, 1 Jul | 1 | 17 Mar, 13 Apr, 12 May, 26 May, 30 Jun |
| 17 | Female | 40 | 1 | Breast cancer | T2N2M0 | None | 1 cycle of capecitabine and 4 cycles of AC | 13 Mar, 20 Apr, 12 May, 3 Jun, 26 Jun | 2 | 12 Mar, 23 Mar, 17 Apr, 11 May, 27 May, 25 Jun, 15 Jul |
| 18 | Female | 61 | 1 | Rectal cancer | T2N1M1 | Hypertension | 2 cycles of FOLFOX and 2 cycles of DC | 12 May, 26 May, 16 Jun, 16 Jul | 1 | 24 Apr, 27 Apr, 11 May, 12 Jun, 14 Jul |
| 19 | Male | 52 | 1 | Rectal cancer | T4N1M0 | Diabetes | 4 cycles of capecitabine | 16 Apr, 19 May, 12 Jun, 6 Jul | 0 | 14 Apr, 18 May, 10 Jun, 3 Jul |
| 20 | Female | 51 | 1 | Rectal cancer | rT0N0M1 | None | 4 cycles of XELOX+PD-1 inhibitor | 18 Apr, 7 May, 1 Jun, 3 Jul | 4 | 16 Apr, 5 May, 29 May, 1 Jul |
| 21 | Female | 37 | 1 | Colon cancer | T3N1M1 | None | 7 cycles of FOLFIRI+bevacizumab | 21 Mar, 8 Apr, 8 May, 28 May, 15 Jun, 1 Jul, 20 Jul | 2 | 19 Mar, 7 Apr; 5 May, 27 May, 12 Jun, 29 Jun, 16 Jul |
| 22 | Male | 37 | 1 | Colon cancer | T4N2bM1 | None | 4 cycles of FOLFIRI+bevacizumab | 15 May, 31 May, 15 Jun, 6 Jul | 2 | 14 May, 29 May, 12 Jun, 2 Jul, 29 Jul |
| 23 | Male | 47 | 1 | Colon cancer | T2N1M0 | None | 2 cycles of capecitabine and 2 cycles of XELOX | 12 Apr, 10 May, 3 Jun, 25 Jun | 1 | 8 Apr, 11 Apr, 9 May, 23 May, 1 Jun, 24 Jun |
| 24 | Male | 63 | 1 | Colon cancer | T3N1M1 | Hypertension | 5 cycles of XELOX+bevacizumab | 3 Apr, 1 May, 22 May, 17 Jun, 7 Jul | 1 | 2 Apr, 30 Apr, 15 May, 15 Jun, 3 Jul |
| 25 | Male | 58 | 1 | NPC | T3N2M0 | None | 2 cycles of DP; RT and 1 cycle of cisplatin | 8 Apr, 1 May, 11 Jun | 2 | 6 Apr, 30 Apr, 23 May, 8 Jun, 26 Jun |
| 26 | Male | 41 | 1 | NPC | T3N2M0 | None | 2 cycles of GP+PD-1 inhibitor; RT and 2 cycles of cisplatin+PD-1 inhibitor | 26 Mar, 19 Apr, 15 May, 7 Jun | 2 | 25 Mar, 17 Apr, 29 May |
| 27 | Male | 62 | 1 | NPC | T4N2M0 | None | 3 cycles of abraxane+nedaplatin | 9 Mar, 1 Apr, 18 Jun | 2 | 8 Mar, 31 Mar, 28 May, 15 Jun |
| 28 | Female | 59 | 1 | NPC | rT0N1M0 | None | 2 cycles of GP and 2 cycles of GP+PD-1 | 19 May, 9 Jun, 1 Jul, 24 Jul | 2 | 21 Apr, 15 May, 3 Jun, 6 Jun, 30 Jun, 20 Jul |
| 29 | Male | 40 | 1 | NPC | T3N2M0 | None | 2 cycles of DP; RT and 2 cycles of cisplatin | 17 Apr, 8 May, 1 Jun, 23 Jun | 2 | 15 Apr, 6 May, 26 May |
| 30 | Male | 59 | 1 | Oesophagus cancer | T4N2M0 | None | 3 cycles of docetaxel+S1 | 1 May, 29 May, 25 Jun | 2 | 30 Apr, 6 May, 28 May, 22 Jun |
| 31 | Male | 67 | 2 | Oesophagus cancer | T3N1M1 | None | 2 cycles of TP | 18 Mar, 12 May | 1 | 17 Mar, 11 May, 26 May |
| 32 | Male | 57 | 1 | Oesophagus cancer | T4aN2M0 | Hypertension and diabetes | 3 cycles of capecitabine+nedaplatin+PD-1 inhibitor | 23 Mar, 8 Jun, 3 Jul | 1 | 20 Mar, 1 Jun, 2 Jul |
| 33 | Male | 64 | 1 | Gastric cancer | T3N2M1 | None | 3 cycles of EP | 22 May, 11 Jun, 7 Jul | 1 | 15 Apr, 20 May, 8 Jun, 4 Jul |
| 34 | Male | 55 | 1 | Gastric cancer | T3N3M1 | None | 3 cycles of oxaliplatin+S1 | 25 Mar, 18 Apr, 10 May | 0 | 24 Mar, 16 Apr, 9 May, 22 May |
| 35 | Female | 48 | 1 | Cervical cancer | IIB (FIGO) | None | 3 cycles of DP | 22 May, 12 Jun, 7 Jul | 1 | 22 Apr, 20 May, 10 Jun, 3 Jul |
| 36 | Female | 60 | 1 | Ovarian cancer | IIIc (FIGO) | None | 4 cycles of etoposide+apatinib | 23 Mar, 21 Apr, 6 May, 29 May | 2 | 23 Mar, 20 Apr, 5 May, 28 May |
| 37 | Female | 62 | 1 | Ampullary carcinoma | T4N0M1 | None | 1 cycle of capecitabine+temozolomide and 1 cycle of abraxane | 2 Apr, 1 Jun | 1 | 31 Mar, 28 May, 5 Jun |
| 38 | Male | 71 | 1 | Soft tissue sarcoma | T3N0M0 G3 | None | 2 cycles of gemcitabine+anlotinib+PD-1 inhibitor | 5 Jun, 3 Jul | 0 | 20 May, 3 Jun, 4 Jun, 29 Jun |
| 39 | Male | 41 | 1 | Glioblastoma | None | 3 cycles of temozolomide | 24 Apr, 22 May, 19 Jun | 0 | 23 Apr, 19 May, 17 Jun |
PS: performance status; NPC: nasopharyngeal cancer; NSCLC: non-small cell lung cancer; GP: gemcitabine+cisplatin; FOLFOX: oxaliplatin+5-fluorouracil+leucovorin; FOLFIRI: irinotecan+5-fluorouracil+leucovorin; EP: etoposide+cisplatin; XELOX: oxaliplatin+capecitabine; AC: adriamycin+cyclophosphamide; RT: radiotherapy; PP: pemetrexed+cisplatin; TP: paclitaxel+cisplatin; DC: docetaxel+carboplatin; DP: docetaxel+cisplatin; S1: tegafur gimeracil oteracil potassium capsule.